Therapeutic | Cixutumumab |
Target | IGF1R |
Heavy Chain | EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSS |
Light Chain | SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | Dyax Human Phage Display |
INN Year Proposed | 2008 |
INN Year Recommended | 2009 |
Companies Involved | Eli Lilly, ImClone Systems, M. D. Anderson Cancer Center, National Cancer Institute (USA) |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Breast cancer, Colorectal cancer, Head and neck cancer, Liver cancer, Neuroendocrine tumours, Non-small cell lung cancer, Oesophageal cancer, Pancreatic cancer, Prostate cancer, Rhabdomyosarcoma, Sarcoma, Soft tissue sarcoma, Solid tumours, Thymoma |
Notes |